4-benzyloxy-2-fluoro-phenyl acetic acid | 607713-92-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-benzyloxy-2-fluoro-phenyl acetic acid
• 英文别名: 4-benzyloxy-2-fluoro-phenyl-acetic acid；2-(2-fluoro-4-phenylmethoxyphenyl)acetic acid
• CAS: 607713-92-8
• 化学式: C₁₅H₁₃FO₃
• 分子量: 260.265
• InChiKey: OKMXEYFPGAZRFY-UHFFFAOYSA-N

物化性质

• 沸点：
  406.3±35.0 °C(Predicted)
• 密度：
  1.264±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-benzyloxy-2-fluoro-phenyl acetic acid 、 溴甲基乙酸酯 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 6.0h， 以57%的产率得到acetoxymethyl 4-benzyloxy-2-fluoro-phenyl-acetate
  参考文献：
  名称：

  4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity

  摘要：

  公式1的化合物 1 其中，变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，适用于治疗可用视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。

  公开号：

  US20030191181A1
• 作为产物：
  描述：

  2-(2-氟-4-羟基苯基)乙酸甲酯 在 甲醇 、 lithium hydroxide monohydrate 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 4-benzyloxy-2-fluoro-phenyl acetic acid
  参考文献：
  名称：

  [EN] HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF
  [FR] CONJUGUÉS LIÉS À HSP90 ET FORMULATIONS DE CEUX-CI

  摘要：

  设计了活性药物与靶向基团（如HSP90结合基团）通过连接剂相连的共轭物和包含这种共轭物的制剂。还提供了制备和使用这种共轭物及其制剂的方法。

  公开号：

  WO2022047008A1

文献信息

• 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：——

  公开号：US20030207937A1

  公开（公告）日：2003-11-06

  Compounds of the formula 1 where the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  具有公式1的化合物，其中变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，并且适用于治疗可通过视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。
• Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A
  申请人：——

  公开号：US20040077721A1

  公开（公告）日：2004-04-22

  vitamin A, or a derivative of vitamin A having vitamin A like activity is co-administered with inhibitors of the CP450RAI1 and/or of CP450RAI2 enzymes for the purpose of treating diseases and conditions in mammals, including humans, which diseases or conditions are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid.

  维生素A，或具有维生素A活性的维生素A衍生物与CP450RAI1和/或CP450RAI2酶的抑制剂共同给药，用于治疗哺乳动物，包括人类的疾病和状况，这些疾病或状况可以通过施用视黄酸化合物或通过哺乳动物机体自然存在的视黄酸来预防、治疗、改善或延迟其发作。
• 4-[(8-ETHYNYL, 8-VINYL OR 8-ETHYNYL-METHYL)-6-CHROMANOYL]-BENZOIC AND 2-[4-[(8-ETHYNYL, 8-VINYL OR 8-ETHYNYL-METHYL)-6-CHROMANOYL]-PHENYL]-ACETIC ACID, THEIR ESTERS AND SALTS HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY
  申请人：Allergan, Inc.

  公开号：US06740676B2

  公开（公告）日：2004-05-25

  Compounds of Formula 1: wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  式1的化合物：其中变量在规范中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，并适用于治疗哺乳动物的疾病，这些疾病可用视黄醇治疗，或受到或响应于生物体的本地视黄酸的控制。含有本发明化合物的制剂也可以与视黄醇和/或维生素A一起共同使用，以增强或延长含有视黄醇、维生素A或生物体本地视黄酸的药物的效果。
• 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：Allergan, Inc.

  公开号：US07351737B2

  公开（公告）日：2008-04-01

  Compounds of the formula where the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  式中变量的化合物具有细胞色素P450RAI-1和P450RAI-2的抑制活性，并适用于治疗哺乳动物的疾病，这些疾病可用维甲酸治疗，或者受到机体本身的视黄酸的控制或反应。含有本发明化合物的制剂也可以与维甲酸和/或维生素A共同使用，以增强或延长含有维甲酸、维生素A或机体本身的视黄酸的药物的效果。
• SUBSTITUTED CHROMAN DERIVATIVES HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY
  申请人：Allergan, Inc.

  公开号：EP1485368A1

  公开（公告）日：2004-12-15